NYSE: NNVC
NANOVIRICIDES, INC.CIK 0001379006 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade NNVC commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
NanoViricides prices $3.7M registered direct offering at $1.53/share; net proceeds $3.5M
6 material changes detected. Sign up free to read the summary.
NanoViricides launches at-the-market offering of up to $4.0M at $1.51/share
4 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-K filed Sep 28, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Statements of Operations
| Description | Year ended June 30, 2026 | Year ended June 30, 2025 |
|---|---|---|
| OPERATING EXPENSES | ||
| Research and development | 4,707,625 | 5,549,101 |
| General and administrative | 3,598,736 | 4,042,544 |
| Total operating expenses | 8,306,361 | 9,591,645 |
| LOSS FROM OPERATIONS | (8,306,361) | (9,591,645) |
| OTHER INCOME (EXPENSE): | ||
| Interest income | 87,852 | 124,828 |
| Interest expense | — | (149) |
| Other income, net | 87,852 | 124,679 |
| NET LOSS | (8,218,509) | (9,466,966) |
| Net loss per common share- basic and diluted | (0.41) | (0.63) |
| Weighted average common shares basic and diluted | 20,187,751 | 15,116,548 |
Balance Sheet
| Description | June 30, 2026 | June 30, 2025 |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | 2,794,110 | 1,558,564 |
| Prepaid expenses | 368,513 | 112,146 |
| Total current assets | 3,162,623 | 1,670,710 |
| Property and equipment, net | 6,401,192 | 6,833,891 |
| Intangible assets, net | 308,769 | 317,039 |
| OTHER ASSETS | ||
| Service agreements | 1,030 | 2,445 |
| Total assets | 9,873,614 | 8,824,085 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | 323,816 | 459,094 |
| Accounts payable related party | 828,577 | 821,456 |
| Accrued expenses | 38,331 | 25,969 |
| Total current liabilities | 1,190,724 | 1,306,519 |
| COMMITMENTS AND CONTINGENCIES (NOTE 11) | ||
| STOCKHOLDERS’ EQUITY: | ||
| Series A convertible preferred stock, $0.00001 par value, 10,000,000 shares designated, 918,809 and 905,717 shares issued and outstanding, at June 30, 2026 and 2025, respectively. (Note 9) | 9 | 9 |
| Common stock, $0.00001 par value; 150,000,000 shares authorized, 23,008,308 and 16,606,832 shares issued and outstanding at June 30, 2026 and 2025, respectively. (Note 8) | 230 | 166 |
| Additional paid-in capital | 165,743,021 | 156,359,252 |
| Accumulated deficit | (157,060,370) | (148,841,861) |
| Total stockholders’ equity | 8,682,890 | 7,517,566 |
| Total liabilities and stockholders’ equity | 9,873,614 | 8,824,085 |
Statements of Cash Flows
| Description | Year ended June 30, 2026 | Year ended June 30, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | (8,218,509) | (9,466,966) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Preferred shares issued as compensation | 49,619 | 60,722 |
| Common shares issued as compensation and for services | 317,833 | 162,625 |
| Warrants granted to Scientific Advisory Board | 503 | 679 |
| Depreciation | 517,016 | 735,536 |
| Amortization | 8,270 | 8,269 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses | (256,367) | 60,596 |
| Other assets | 1,415 | 12,117 |
| Accounts payable | (135,278) | 82,824 |
| Accounts payable related parties | 7,121 | 101,417 |
| Accrued expenses | 12,362 | (236,498) |
| NET CASH USED IN OPERATING ACTIVITIES | (7,696,015) | (8,478,679) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | (84,317) | (56,964) |
| NET CASH USED IN INVESTING ACTIVITIES | (84,317) | (56,964) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Net proceeds from sale of common stock | 1,909,121 | 5,296,429 |
| Net proceeds from the sale of common stock and common stock warrants | 7,106,757 | — |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 9,015,878 | 5,296,429 |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | 1,235,546 | (3,239,214) |
| Cash and cash equivalents at beginning of period | 1,558,564 | 4,797,778 |
| Cash and cash equivalents at end of period | 2,794,110 | 1,558,564 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: | ||
| Interest paid | — | 149 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗